Stock Rating Downgrade
In the last week the Value Trend Rating for EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) weakened from C to D reflecting eroding fundamentals and low Appreciation Potential.
Recent Price Action
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) stock closed at $7.13 on 3/7/25 after a large increase of 4.5%. This advance was accompanied by normal trading volume. Relative to the market the stock has been weak over the last nine months but has risen 14.4% during the last week.
Current PriceTarget Research Rating
EyePoint Pharmaceuticals has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. EyePoint Pharmaceuticals has a neutral Appreciation Score of 41 but a poor Power Rating of 25, and the Negative Value Trend Rating results.
Be the first to comment